CervoMed receives U.S. patent for neflamapimod in pure DLB to 2042

CervoMed Inc. (NASDAQ: CRVO) announced it has received a notice of allowance from the United States Patent and Trademark Office for a new patent covering the use of its drug candidate neflamapimod in the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, a condition referred to as "pure DLB."

The patent covers treatment of DLB without substantial tau pathology, which can be identified through plasma levels of pTau or brain imaging. The company said the patent is expected to provide intellectual property protection into 2042, with the possibility of a longer term through patent term extension.

According to the company, there are currently no approved treatments for DLB in the United States or the European Union.

CervoMed's Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients enriched for those without Alzheimer's disease co-pathology. In November 2025, the company announced it had reached alignment with the U.S. Food and Drug Administration on a potential registration path for neflamapimod in DLB. The company noted that initiation of a Phase 3 trial remains subject to securing a partnership and additional financing.

Neflamapimod is an oral small molecule that inhibits an enzyme involved in neuroinflammation and neurodegeneration. CervoMed is also evaluating the drug in a Phase 2a trial for nonfluent variant primary progressive aphasia, with interim biomarker data expected in early fourth quarter 2026, and plans to dose the first patient in its EXPERTS-ALS Phase 2a trial in the fourth quarter of 2026.

You May Also Be Interested In

• CervoMed (CRVO) PT Lowered to $18 at Canaccord
• Cloudflare wins FedRAMP High and GovRAMP Moderate authorizations
• La Rosa Holdings launches strategic review, regains Nasdaq compliance